Source Count: 16 | Weighted Score: 37 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: April 15, 2026
Keywords: congenital insensitivity to pain, CIP, CIPA, SCN9A, Nav1.7, nociception, channelopathy, HSAN, hereditary sensory neuropathy, pain genetics, painlessness, analgesic, NGF, NTRK1, sodium channel
Category Tags: y5 extreme physical paranormal
Cross-References: X_3_09 — Anesthesia & Pain Management · Z_1_08 — Ion Channels · K_5_18 — Working Memory

QUICK SUMMARY

Congenital insensitivity to pain (CIP) encompasses a group of rare inherited conditions in which individuals are born with absent or severely diminished pain perception while retaining other sensory modalities (touch, pressure, temperature — though some subtypes impair these as well). The most studied form is caused by loss-of-function mutations in SCN9A, the gene encoding the voltage-gated sodium channel Nav1.7 — a discovery published in 2006 by C. Geoffrey Woods (Cambridge) based on a consanguineous Pakistani family. CIP conditions — classified within the Hereditary Sensory and Autonomic Neuropathies (HSANs) — affect an estimated 1 in 1,000,000 individuals. Far from being a "superpower," CIP carries extreme medical danger: patients sustain severe injuries, burns, fractures, and joint damage without protective pain withdrawal, often resulting in disability and reduced life expectancy. The study of CIP has provided crucial insights into pain neurobiology and has driven the development of Nav1.7-targeted analgesic drugs.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 SCN9A Mutations and Nav1.7 Channelopathy

• Evidence: In 2006, C. Geoffrey Woods et al. (Cambridge University) studied six children from three consanguineous Pakistani families who had never experienced pain despite normal intelligence, touch sensation, and temperature perception. They identified homozygous loss-of-function mutations in SCN9A (chromosome 2q24.3), encoding the Nav1.7 voltage-gated sodium channel expressed in peripheral nociceptive (pain-sensing) neurons. Nav1.7 is essential for pain signal initiation — without it, nociceptors cannot generate action potentials in response to tissue damage. This was a landmark discovery: a single gene whose loss abolishes pain perception across all modalities (thermal, mechanical, chemical, inflammatory). [KEY FINDING]
• Primary Source: Cox, James, et al. "An SCN9A Channelopathy Causes Congenital Inability to Experience Pain." Nature 444 (2006): 894–898. DOI: 10.1038/nature05413

1.2 Clinical Consequences of CIP

• Evidence: CIP patients characteristically present with:
• Self-inflicted injuries in infancy (biting tongue, lips, fingers before learning to inhibit)
• Multiple fractures that go unnoticed for days or weeks
• Burns without withdrawal response
• Charcot joints (neuropathic arthropathy) from cumulative unperceived joint damage
• Corneal abrasions from absent blink reflex to foreign bodies
• Osteomyelitis from undetected infections

Nagasako, Oaklander, and Dworkin (2003) reviewed the literature on CIP (then classified as HSAN Type V or CIP/CIPA), documenting that most affected individuals had significantly reduced life expectancy. The standard clinical observation — repeatedly confirmed — is that pain is not a design flaw but a critical survival mechanism.

• Primary Source: Nagasako, Erica, Anne Oaklander, and Robert Dworkin. "Congenital Insensitivity to Pain: An Update." Pain 101.3 (2003): 213–219. DOI: 10.1016/S0304-3959(02)00482-7

1.3 HSAN Classification (Types I–V)

• Evidence: The Hereditary Sensory and Autonomic Neuropathies (HSANs) are classified into five types:
• HSAN I: autosomal dominant, adult onset, progressive sensory loss, ulcero-mutilating complications (SPTLC1 gene)
• HSAN II: autosomal recessive, congenital, loss of all sensory modalities (WNK1/HSN2 gene)
• HSAN III (Riley-Day syndrome/Familial Dysautonomia): autosomal recessive, Ashkenazi Jewish predominance, autonomic dysfunction, reduced pain/temperature, IKBKAP/ELP1 gene
• HSAN IV (CIPA — Congenital Insensitivity to Pain with Anhidrosis): autosomal recessive, absent pain + absent sweating, NTRK1 gene (encoding TrkA receptor for nerve growth factor)
• HSAN V: absent pain with preserved sweating, NGFB gene (nerve growth factor beta)

Indo et al. (1996) identified the NTRK1 mutation causing HSAN IV, demonstrating that the nerve growth factor signaling pathway is essential for nociceptor development.

• Primary Source: Indo, Yasuhiro, et al. "Mutations in the TRKA/NGF Receptor Gene in Patients with Congenital Insensitivity to Pain with Anhidrosis." Nature Genetics 13.4 (1996): 485–488. DOI: 10.1038/ng0896-485

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 SCN9A Gain-of-Function: The Opposite Phenotype

• Evidence: Remarkably, gain-of-function mutations in the same SCN9A gene cause the opposite phenotype: extreme chronic pain conditions. Yang et al. (2004) identified SCN9A gain-of-function mutations in primary erythromelalgia (burning pain in extremities), and Fertleman et al. (2006) demonstrated that different SCN9A mutations cause paroxysmal extreme pain disorder (PEPD — severe episodic pain in rectal, ocular, and submandibular areas). This bidirectional relationship — loss-of-function = no pain, gain-of-function = extreme pain — confirmed Nav1.7 as a master regulator of pain perception and a prime analgesic drug target.
• Primary Source: Yang, Yong, et al. "Mutations in SCN9A, Encoding a Sodium Channel Alpha Subunit, in Patients with Primary Erythermalgia." Journal of Medical Genetics 41.3 (2004): 171–174. DOI: 10.1136/jmg.2003.012153

2.2 Nav1.7 as Drug Target

• Evidence: The discovery that Nav1.7 loss abolishes pain without affecting other neural functions made it an "ideal" analgesic target — potentially offering pain relief without the addiction, sedation, and tolerance problems of opioids. Pharmaceutical companies including Merck, Pfizer, Genentech, Xenon Pharmaceuticals, and Amgen invested heavily in Nav1.7 inhibitor development. However, clinical translation has proven difficult: achieving sufficient selectivity for Nav1.7 over structurally similar sodium channels (Nav1.1–Nav1.9), adequate tissue penetration, and consistent efficacy has been challenging. As of 2025, no Nav1.7-specific analgesic has achieved FDA approval, though several candidates remain in clinical trials.
• Primary Source: Dib-Hajj, Sulayman, et al. "Sodium Channels in Normal and Pathological Pain." Annual Review of Neuroscience 33 (2010): 325–347. DOI: 10.1146/annurev-neuro-060909-153234

2.3 Anosmia and Nav1.7

• Evidence: Weiss et al. (2011) discovered that individuals with SCN9A loss-of-function mutations are also anosmic (unable to smell) — revealing that Nav1.7 plays a previously unsuspected role in olfactory neuron signaling. This finding demonstrated that Nav1.7's function extends beyond nociception, complicating the simple narrative that it is exclusively a "pain channel." The anosmia is clinically important but less medically dangerous than the pain insensitivity.
• Primary Source: Weiss, Jan, et al. "Loss-of-Function Mutations in Sodium Channel Nav1.7 Cause Anosmia." Nature 472 (2011): 186–190. DOI: 10.1038/nature09975

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Gene Therapy for Chronic Pain

• Evidence: The theoretical possibility of using gene therapy to selectively suppress SCN9A expression in nociceptive neurons offers a potential long-term solution for chronic pain. Moreno et al. (2021, Science Translational Medicine) demonstrated in mice that CRISPR-based epigenetic silencing of SCN9A in dorsal root ganglia reduced pain behaviors. Translation to humans faces significant hurdles: delivery specificity, off-target effects, the anosmia problem, and the need for reversibility. The approach remains preclinical.

3.2 Evolutionary Significance of Pain Variability

• Evidence: Population-level variation in pain sensitivity (partly mediated by SNPs in SCN9A, COMT, OPRM1, and other genes) suggests that pain thresholds are under ongoing selection. Researchers speculate that different ecological environments may have selected for different pain sensitivity thresholds — but evidence linking specific SCN9A variants to adaptive advantages in particular populations remains preliminary.

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Pain Immunity as Spiritual Achievement

• Evidence: Some popular sources claim that certain meditation practitioners, yogis, or practitioners of extreme body modification achieve "immunity to pain" comparable to CIP. While meditation and hypnosis can modulate pain perception (documented in fMRI studies showing reduced anterior cingulate and insula activation), this represents cortical modulation of intact nociceptive pathways — fundamentally different from the peripheral nociceptor silence of CIP. No meditation practice produces the tissue-damage risks of true CIP. [DEBUNKED as equivalence]

Counter-Arguments & Criticisms

1. Waxman (2010) cautioned against oversimplifying the "Nav1.7 = pain" narrative — pain is processed by a complex network of peripheral and central mechanisms, and Nav1.7 is one component. The difficulty of translating SCN9A findings into effective drugs underscores this complexity.

1. Some CIP researchers note an ethical tension in studying affected families (often in consanguineous communities in Pakistan, Jordan, and the Arabian Peninsula) — power imbalances between Western research institutions and participants require careful ethical navigation.

1. The focus on rare monogenic pain disorders, while scientifically productive, may not translate directly to common chronic pain conditions, which typically involve polygenic and environmental factors.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Cox, James, et al | 2006 | "An SCN9A Channelopathy Causes Congenital Inability to Experience Pain" | Nature | ∅ | 444::894–898 | ∅ | ∅ | doi:10.1038/nature05413 | ∅ | ∅ | ∅
2. Indo, Yasuhiro, et al | 1996 | "Mutations in the TRKA/NGF Receptor Gene in Patients with Congenital Insensitivity to Pain with Anhidrosis" | Nature Genetics | ∅ | 13.4::485–488 | ∅ | ∅ | doi:10.1038/ng0896-485 | ∅ | ∅ | ∅
3. Nagasako, Erica, Anne Oaklander; Robert Dworkin. | 2003 | "Congenital Insensitivity to Pain: An Update" | Pain | ∅ | 101.3::213–219 | ∅ | ∅ | doi:10.1016/S0304-3959(02)00482-7 | ∅ | ∅ | ∅
4. Yang, Yong, et al | 2004 | "Mutations in SCN9A, Encoding a Sodium Channel Alpha Subunit, in Patients with Primary Erythermalgia" | Journal of Medical Genetics | ∅ | 41.3::171–174 | ∅ | ∅ | doi:10.1136/jmg.2003.012153 | ∅ | ∅ | ∅
5. Dib-Hajj, Sulayman, et al | 2010 | "Sodium Channels in Normal and Pathological Pain" | Annual Review of Neuroscience | ∅ | 33::325–347 | ∅ | ∅ | doi:10.1146/annurev-neuro-060909-153234 | ∅ | ∅ | ∅
6. Weiss, Jan, et al | 2011 | "Loss-of-Function Mutations in Sodium Channel Nav1.7 Cause Anosmia" | Nature | ∅ | 472::186–190 | ∅ | ∅ | doi:10.1038/nature09975 | ∅ | ∅ | ∅
7. Waxman, Stephen | 2010 | "Channelopathic Pain: A Growing but Still Small List of Model Disorders" | Neuroscientist | ∅ | 16.5::519–531 | ∅ | ∅ | doi:10.1177/1073858410368774 | ∅ | ∅ | ∅
8. Fertleman, Caroline, et al | 2006 | "SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes" | Neuron | ∅ | 52.5::767–774 | ∅ | ∅ | doi:10.1016/j.neuron.2006.10.006 | ∅ | ∅ | ∅
9. Bennett, David; C | 2014 | "Painful and Painless Channelopathies" | Lancet Neurology | ∅ | 13.6::587–599 | Geoffrey Woods. | ∅ | doi:10.1016/S1474-4422(14)70024-9 | ∅ | ∅ | ∅
10. Goldberg, Yoel, et al | 2007 | "Loss-of-Function Mutations in the Nav1.7 Gene Underlie Congenital Indifference to Pain in Multiple Human Populations" | Clinical Genetics | ∅ | 71.4::311–319 | ∅ | ∅ | doi:10.1111/j.1399-0004.2007.00790.x | ∅ | ∅ | ∅
11. Basbaum, Allan, et al | 2009 | "Cellular and Molecular Mechanisms of Pain" | Cell | ∅ | 139.2::267–284 | ∅ | ∅ | doi:10.1016/j.cell.2009.09.034 | ∅ | ∅ | ∅
12. Moreno, Ana, et al. eaay9056 | 2021 | "Long-Lasting Analgesia via Targeted In Situ Repression of NaV1.7 in Mice" | Science Translational Medicine | ∅ | 13.584:: | ∅ | ∅ | doi:10.1126/scitranslmed.aay9056 | ∅ | ∅ | ∅
13. Dyment, David, et al | 2013 | "Recent Advances in the Genetics of Pain Insensitivity" | Current Genomics | ∅ | 14.6::363–383 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
14. Haga, Noriyuki, et al | 2015 | "Hereditary Sensory and Autonomic Neuropathy Types IV and V in Japan" | Pediatrics International | ∅ | 57.1::30–36 | ∅ | ∅ | doi:10.1111/ped.12538 | ∅ | ∅ | ∅
15. Minett, Michael, et al | 2015 | "Endogenous Opioids Contribute to Insensitivity to Pain in Humans and Mice Lacking Sodium Channel Nav1.7" | Nature Communications | ∅ | 6::8967 | ∅ | ∅ | doi:10.1038/ncomms9967 | ∅ | ∅ | ∅
16. Wall, Patrick; Ronald Melzack | 2006 | ∅ | Textbook of Pain | ∅ | ∅ | Edinburgh: Churchill Livingstone | 5th | isbn:9780443047572 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: April 15, 2026

Corrections

• 2 truncated DOIs in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — each was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/S0304-3959(02)00482-7, 10.1016/S1474-4422(14)70024-9. Corpus hygiene campaign, Phase 4, 2026-07-29.

• Textbook of Pain — ISBN corrected from 9780443072874 to 9780443047572, verified against Open Library (Textbook of pain, Ronald Melzack, Patrick D. Wall). The previous number failed its check digit.